Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer

BACKGROUND: Markers to predict the efficacy of bevacizumab treatment have been not fully validated in most cancers, including metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential role of lactate dehydrogenase (LDH) in predicting the survival benefit from first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chenxi, Jiang, Chang, Liao, Fangxin, Rong, Yuming, Cai, Xiuyu, Guo, Guifang, Qiu, Huijuan, Chen, Xuxian, Zhang, Bei, He, Wenzhuo, Xia, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136961/
https://www.ncbi.nlm.nih.gov/pubmed/25143746
http://dx.doi.org/10.2147/OTT.S64559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136961/
https://www.ncbi.nlm.nih.gov/pubmed/25143746
http://dx.doi.org/10.2147/OTT.S64559

Ejemplares similares